[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

4 clusters · 6 sources · 52 days · First seen · Last updated

Celltrion biosimilar market expansion

Overview

Celltrion continues to expand its global biosimilar market share, particularly in autoimmune and oncology treatments. In the United States, the ustekinumab biosimilar Stekyma reached a 16.2% market share in July, marking a 6 percentage point increase over five months. The company’s oncology portfolio remains strong in the U.S., with Truxima holding 38.6% and Inflectra at 30.7%.

In Europe, the subcutaneous formulation Remsima SC has achieved record shares in the EU5, including 49% in Germany, 35% in France, and 31% in Italy. Asian markets remain a stronghold; Remsima maintains dominant positions in Singapore (93%), Hong Kong (84%), Thailand (78%), and Malaysia (72%).

A significant milestone was reached in Japan, where Remsima (infliximab) secured a 48% market share in July, surpassing original brand-name drugs for the first time since its launch 11 years ago. Celltrion attributed this in Japan to a dual-track distribution strategy involving its local partner, Nippon Kayaku, and its own Japanese subsidiary. Other products in Japan include Yuflyma (adalimumab) at 21% market share, Herzuma (trastuzumab) at 78%, and Vegzelma (bevacizumab) at 64%.

Celltrion plans to leverage its direct sales networks to launch high-margin products like Omlyclo and intends to launch Remsima SC in Japan in 2027.

Entities

Celltrion · IQVIA · Cardiol Therapeutics Inc. · Omlyclo · Samsung Biologics

Timeline

  1. [BUSINESS] 3 sources
    Celltrion's Remsima reaches number one in Japan's infliximab market

    Celltrion's Remsima has become the top-selling infliximab in Japan, capturing a 48% market share and surpassing original drugs 11 years after its local launch.

  2. [BUSINESS] 3 sources
    Celltrion expands global biosimilar market share in US, Europe, and Asia

    Celltrion reports rising global market shares for its biosimilars, with Stekyma reaching 16.2% in the U.S. and Remsima SC seeing record growth across major European and Asian markets.

  3. [BUSINESS] 2 sources
    Celltrion secures leading market shares for biosimilars in Asia

    Celltrion has secured leading market shares for its Remsima and oncology biosimilars across Singapore, Hong Kong, Thailand, and Malaysia, driven by its direct sales networks.

  4. [BUSINESS] 3 sources
    Celltrion posts record Q2 sales of 1.4 trillion won, driven by high‑margin biosimilars

    Celltrion reported Q2 sales of 1.4 trillion won (up 45% YoY) and operating profit of 452 billion won (up 86% YoY), with a 32.4% margin. New biosimilars made up 65% of sales, beating Samsung Biologics in revenue

Sources

biotimes.co.kr · biz.heraldcorp.com · joongboo.com · kormedi.com · kyeonggi.com · techholic.co.kr

This summary has been updated 2 times: see revision history